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FUS (fused in sarcoma) is a component of the cellular
response to topoisomerase I–induced DNA breakage and
transcriptional stress
Maria Isabel Martinez-Macias1 , Duncan AQ Moore1, Ryan L Green2, Fernando Gomez-Herreros1,3 , Marcel Naumann4,6,
Andreas Hermann4,5,6, Philip Van Damme7, Majid Hafezparast2 , Keith W Caldecott1
FUS (fused in sarcoma) plays a key role in several steps of RNA
metabolism, and dominant mutations in this protein are asso-
ciated with neurodegenerative diseases. Here, we show that FUS
is a component of the cellular response to topoisomerase I
(TOP1)–induced DNA breakage; relocalising to the nucleolus in
response to RNA polymerase II (Pol II) stalling at sites of TOP1-
induced DNA breaks. This relocalisation is rapid and dynamic,
reversing following the removal of TOP1-induced breaks and
coinciding with the recovery of global transcription. Importantly,
FUS relocalisation following TOP1-induced DNA breakage is as-
sociated with increased FUS binding at sites of RNA polymerase I
transcription in ribosomal DNA and reduced FUS binding at sites
of RNA Pol II transcription, suggesting that FUS relocates from
sites of stalled RNA Pol II either to regulate pre-mRNA processing
during transcriptional stress or to modulate ribosomal RNA
biogenesis. Importantly, FUS-mutant patient ﬁbroblasts are hy-
persensitive to TOP1-induced DNA breakage, highlighting the
possible relevance of these ﬁndings to neurodegeneration.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with
signiﬁcant phenotypic variability but with some common patho-
logical and genetic characteristics (reviewed in references 1, 2, 3).
For example, mutation and/or toxic aggregation of RNA-binding
proteins such as TAR DNA binding protein (TDP-43) and fused in
sarcoma (FUS) have been associated with ALS (4, 5, 6, 7). In recent
years, mutations in several additional RNA-binding proteins have
been associated with neurodegenerative diseases, including EWS
(EWSR1), TAF15 (8), hnRNPA1, hnRNP A2B1 (9), and ataxin-2 (10),
supporting the notion that defects in RNA metabolism can induce
neurodegeneration (11, 12, 13).
ALS is the most common adult-onset motor neuron disease and
is characterized by progressive degeneration of motor neurons.
Although most cases of ALS are sporadic (sALS), 5–10% of cases
have a familial history (fALS) (reviewed in references 2, 11, 14). It is
thought that mutations in TDP-43 and FUS each account for 1–5% of
fALS with a hexanucleotide repeat expansion in C9ORF72 ac-
counting for ~40% (2, 11, 14). FUS is a heterogeneous nuclear ri-
bonucleoprotein (hnRNP) that belongs to the FET/TET family of
RNA-binding proteins, including TAF15 and EWS (15, 16, 17, 18). FUS
modulates multiple aspects of RNA metabolism, including tran-
scription, splicing, microRNA processing, and mRNA transport
(reviewed in references 18, 19, 20). Consequently, it has been
proposed that ALS mutations cause pathological changes in FUS-
regulated gene expression and RNA processing, due either to loss of
normal FUS function, toxic gain of function, or both.
There is increasing evidence that FUS is also a component of the
cellular response to DNA damage (21, 22, 23, 24). For example, FUS is
phosphorylated by the DNA damage sensor protein kinases ATM
and/or DNA-PK following treatment of cells with ionising radiation
(IR) or etoposide (25, 26), and FUS deﬁciency in mice is associated
with increased sensitivity to IR and elevated chromosome instability
(27, 28). In addition, FUS accumulates at sites of laser-induced oxi-
dative DNA damage in amanner that is dependent on the DNA strand
break sensor protein, PARP1 (21,22). FUS interacts directly with poly
(ADP-ribose), the RNA-like polymeric product of PARP1 activity, possibly
promoting its concentration in liquid compartments and recruitment
at DNA strand breaks (21, 22, 29). FUS reportedly also promotes the
repair of DNAdouble-strandbreaks (DSBs) by the nonhomologous end
joining (NHEJ) and homologous recombination pathways for DSB re-
pair (21, 23). Finally, FUS is present at sites of transcription at which RNA
polymerase II (Pol II) is stalled by UV-induced DNA lesions and may
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facilitate the repair of R-loops or other nucleic acid structures induced
by UV-induced transcription-associated DNA damage (24).
The observation that several other RNA-processing factors, in
addition to FUS, are also implicated in the DNA damage response
suggests that there is considerable cross-talk between these
processes (30). However, the nature of the endogenous sources of
DNA damage that might trigger a requirement for FUS and/or other
RNA-processing factors is unknown. Of particular threat to neural
maintenance and function is DNA damage induced by top-
oisomerases, a class of enzymes that remove torsional stress from
DNA by creation of transient DNA strand breaks (31). Usually, these
breaks are resealed by the topoisomerase enzyme at the end of
each catalytic cycle, but on occasion, they can become abortive and
require cellular DNA single- or DSB repair pathways for their re-
moval. If not repaired rapidly or appropriately, topoisomerase-
induced breaks can lead to chromosome translocations and
genome instability in proliferating cells, and cytotoxicity and/or
cellular dysfunction in post-mitotic cells. This is illustrated by the
existence of hereditary neurodegenerative diseases in which af-
fected individuals harbour mutations in tyrosyl DNA phosphodi-
esterase 1 (TDP1) or tyrosyl DNA phosphodiesterase 2 (TDP2) (32,33),
DNA repair proteins with activities dedicated to removing trapped
topoisomerases from DNA breaks (32, 33, 34).
To further address the relationship between ALS and endoge-
nous DNA damage, we have examined the response of FUS to
topoisomerase-induced DNA damage. Here, using a variety of
different cell types, including human spinal motor neurons, we
show that FUS is a component of the cellular response to tran-
scriptional stress induced by topoisomerase I (TOP1)–associated
DNA breakage. Importantly, we ﬁnd that HeLa cells and ALS patient
ﬁbroblasts expressing mutant FUS are hypersensitive to TOP1-
induced DNA breakage, highlighting the possible relevance of
our ﬁndings to ALS disease pathology.
Results
Normal rates of DSB repair in FUS-mutated ALS patient
ﬁbroblasts
It has been reported that siRNA-mediated depletion of FUS results
in reduced DNA DSB repair and that FUS is involved in this process
(21, 23). To examine whether this observation is relevant to
topoisomerase-induced DNA breaks in the context of ALS, we
compared ﬁbroblasts from an ALS patient harbouring the common
disease mutation FUSR521H and an unaffected sibling for DSB repair
kinetics following treatment with the genotoxins camptothecin
(CPT) or etoposide. These genotoxins exert their cytotoxic effects by
triggering the abortive activity of TOP1 and topoisomerase II (TOP2),
thereby inducing TOP1- and TOP2-induced DNA breaks, re-
spectively. Both TOP1- and TOP2-induced DNA breaks are physio-
logically relevant sources of DNA damage that are implicated in
neurodegeneration (32, 33, 35). Surprisingly, immunostaining for
γH2AX, an indirect marker of DSB sites, failed to reveal any dif-
ference in the kinetics of DSB induction and removal between
unaffected and ALS ﬁbroblasts following treatment with either CPT
or etoposide (Fig 1A and B). We also failed to observe any difference
in kinetics of DSB induction and repair following treatment with IR,
which induces DSBs independently of topoisomerase activity (Fig
1C). Together, these experiments suggest that ALS pathology arising
from FUS mutation does not result from defects in the repair of
DSBs induced by topoisomerases or oxidative stress.
FUS relocalises to the nucleolus in response to TOP1-induced DNA
breakage
Despite the results described above, we considered it likely that
FUS is part of the cellular response to DNA damage because this
protein relocalises to sites of laser-induced DNA damage (21, 22).
We, therefore, employed a HeLa cell line stably expressing GFP-FUS
(36) to examine the subcellular localization of this protein before
and after treatment with CPT, a more physiologically relevant
source of DNA damage treatment. Strikingly, we observed a rapid
relocalisation of GFP-FUS into nuclear foci (Fig 2A). This was not the
case following IR, however, suggesting that FUS relocalisation was
not due simply to the induction of DSBs. Subsequent experiments,
in which we co-stained cells for ﬁbrillarin, revealed that the sites of
GFP-FUS accumulation following CPT treatment were restricted to
nucleoli and/or nucleolar caps (Fig 2B). This relocalisation was not
an artefact of FUS overexpression or the GFP tag because a similar
phenomenon was observed with endogenous FUS in A549 cells (Fig
2C) and in primary human ﬁbroblasts (Fig 2D). Notably, we observed
a similar response for GFP-tagged TDP-43, another ALS-associated
protein involved in RNA metabolism, albeit to a lesser extent (Fig
S1B). A similar response was observed for ALS-associated mutant
derivatives of both GFP-FUS (GFP-FUSR521C and GFP-FUSP525L; Fig
S1A) and GFP-TDP-43 (GFP-TDP-43G298S and GFP-TDP-43M337V; Fig
S1C), suggesting that ALS is not caused simply by a defect in the
relocalisation of these proteins to nucleoli.
Because ALS is characterized by progressive neurodegeneration
(14), we wished to conﬁrm that the relocalisation of FUS to nucleoli
induced by CPT in cultured cell lines also occurred in neurons.
Indeed, endogenous FUS similarly relocalised to nucleoli in mouse
cortical neurons following CPT treatment (Fig 3A). Similarly, FUS-GFP
relocalised to nuceoli following CPT treatment in patient-derived
human-induced pluripotent stem cells (hiPSCs) that were gene
edited to express this protein from the endogenous FUS locus,
following their differentiation into human spinal motor neurons
(Fig 3B) (37). That we successfully generatedmotor neurons in these
experiments was conﬁrmed by immunostaining for MAP2 and ChAT
(Fig 3B and C) and by the absence of detectable expression of SOX2
(data not shown). Interestingly, FUSP525L-GFP similarly relocalised to
nucleoli/nucleolar caps in isogenic human spinal motor neurons
following CPT treatment (Fig S2), again suggesting that FUS reloc-
alisation is not markedly affected by ALS-associated mutations.
FUS relocalisation following TOP1-induced DNA breakage is
triggered by RNA Pol II inhibition
Both CPT and IR induce DNA strand breaks, but only CPT induced the
relocalisation of FUS to nucleoli. Consequently, we considered it
unlikely that the nucleolar relocalisation was triggered directly by
DNA breaks. Consistent with this idea, although the SSB sensor
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protein PARP1 triggers GFP-FUS recruitment to sites of oxidative
DNA damage (21, 22), inhibitors of PARP1 failed to disrupt the
relocalisation of FUS to nucleoli/nucleolar caps following CPT treat-
ment (Fig 4A). Similarly, inhibitors of the ataxia telangiectasia and Rad3
related (ATR), ataxia telangiectasiamutated (ATM), andDNA-PK protein
kinases that are the primary sensors of DSBs also failed to prevent FUS
movement to nucleoli (Fig 4B). Importantly, immunostaining for 53BP1
conﬁrmed that whereas only CPT triggered this FUS relocalisation,
DSBs were induced both by CPT and IR (Fig 4C).
Because FUS is implicated in regulating gene transcription (38)
and because TOP1-induced DNA breaks are potent inhibitors of RNA
polymerase progression (39, 40), we considered the possibility that
the relocalisation of FUS to nucleoli following CPT treatment was
triggered by RNA polymerase blockage. Consistent with this idea,
treatment with CPT reduced the rate of transcription in the nucleus
and nucleolus, as measured by 5-ethynyl uridine (EU) pulse la-
belling (Fig 5A, left). Moreover, the relocalisation of FUS to the
nucleolus was rapidly reversible, with the exit of this protein from
the nucleolus following CPT removal coincident with the recovery of
global transcription (Fig 5B). This was not the case for IR, which
consistent with its inability to induce FUS relocalisation did not
reduce the global rate of transcription (Fig 5A, right). To further
examine whether FUS relocalisation was triggered by transcrip-
tional stress, we used the RNA polymerase inhibitor actinomycin D.
Indeed, incubation with actinomycin D at concentrations (4 μM) that
inhibit both RNA polymerase I (Pol I) and RNA Pol II induced rapid
FUS relocalisation to the nucleolus (Fig 5C). However, incubation
with lower concentrations of actinomycin D (5 nM) that inhibit only
Pol I did not trigger FUS relocalisation, suggesting that it is the
inhibition of Pol II that triggers FUS accumulation at nucleoli
(Fig 5C). Consistent with this idea, incubation with CX5461 (41),
a speciﬁc inhibitor of Pol I, failed to trigger FUS relocalisation (Fig
5C). Moreover, CX5461 strongly suppressed CPT-induced relocali-
sation of FUS to nucleoli, with only 25% of the cells showing re-
sidual nucleolar FUS (Fig 5C). Because CX5461 prevents the initiation
of transcription by Pol I, this result suggests that FUS relocali-
sation following TOP1-induced DNA breakage requires Pol I to be
engaged in transcription. Interestingly, 5,6-dichloro-1-β-D-ribo-
furanosylbenzimidazole (DRB), another RNA synthesis inhibitor,
also triggered the recruitment of wild-type GFP-FUS (and the ALS-
associated mutants GFP-FUSR521C and GFP-FUSP525L) to nucleoli
(Figs 5D and S3), and this response was also impaired by CX5461
treatment (Fig 5D). Collectively, these data suggest that the accu-
mulation of FUS at nucleoli requires ongoing Pol I transcriptional
activity and is triggered by Pol II inhibition.
Chromatin binding by FUS is increased at transcriptionally active
rDNA following TOP1-induced DNA breakage
To examine whether the relocalisation of FUS observed by im-
munoﬂuorescence reﬂects a change in FUS activity at themolecular
level, we used chromatin immunoprecipitation to compare the level
of FUS binding at the ribosomal DNA (rDNA) locus and at FOS, a Pol II
transcribed gene and target for TOP1-induced DNA breakage (42,
43). Indeed, these experiments revealed that FUS was bound to the
transcribed region of FOS following induction of the latter gene by
the calcium ionophore A23187, and that this binding decreased
following CPT treatment (Fig 6A). We noted that the total level of FOS
Figure 1. Normal DSB repair kinetics in ﬁbroblasts
from FUSR521H ALS ﬁbroblasts.
(A–C) DSBs were quantiﬁed as γH2AX foci in G1-arrested
ALS-FUSR521H patient and unaffected sibling (Control)
ﬁbroblasts. Cells were DMSO-treated, non-irradiated, or
treated as indicated with either (A) 4 μM CPT for 45 min,
(B) 20 μM etoposide for 30 min, or (C) 2 Gy IR. γH2AX foci
were counted in CENPF-negative cells at the indicated
time points after treatment. Data are the average (±SEM)
of three independent experiments.
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mRNA was reduced following CPT treatment, and that the relative
amount of spliced mRNA was increased, conﬁrming that FOS ex-
pression was impacted by TOP1-induced DNA breakage in these
experiments (Fig 6B and C). In contrast, consistent with our im-
munoﬂuorescence experiments, FUS binding at the rDNA locus
increased >fourfold following treatment with CPT (Fig 6D). Notably,
CPT increased FUS binding at the 18S and ITS-1 regions of rDNA but
not at the promoter, again suggesting that FUS relocalises to the
region of rDNA genes that are engaged by Pol I. Indeed, in agreement
with this idea and with our immunoﬂuorescence experiments, co-
incubation with the Pol I inhibitor CX5461 greatly reduced FUS re-
cruitment at rDNA in response to CPT (Fig 6D). Because CPT also
inhibited nucleolar transcription (see Fig 5A), we considered it likely
that FUS relocalised to rDNA genes at which Pol I was engaged but
stalled. Consistent with this idea, chromatin immunoprecipitation
experiments using the antibody S9.6 identiﬁed elevated levels of
RNA/DNA hybrid and/or R-loop structures at the 18S and ITS1 regions
of rDNA, following CPT treatment (Fig 6E). Similar to FUS relocalisation
and binding, the appearance of these RNA/DNA hybrids at the rDNA
was dependent on Pol I activity (Fig 6E).
ALS patient ﬁbroblasts and HeLa cells expressing ALS-associated
FUS mutations are hypersensitive to TOP1-induced DNA breakage
Collectively, our results suggest that FUS is part of a cellular re-
sponse to Pol II transcriptional stress, including that triggered by
TOP1-induced DNA breaks, in which this RNA-processing factor
relocalises to sites of ribosomal RNA (rRNA) transcription. To de-
termine whether this response is important for cell survival, we
compared the sensitivity of ﬁbroblasts from a patient with ALS
harbouring the mutation FUSR521H with those of the unaffected
sibling control. Notably, the ALS patient ﬁbroblasts exhibited in-
creased sensitivity to CPT (Fig 7A, left). In contrast, these cells
exhibited normal levels of sensitivity to IR, consistent with the
Figure 2. FUS relocalises to nucleoli in response to
TOP1-induced DNA breakage.
(A) GFP-FUS ﬂuorescence was detected in untreated
HeLa cells and in HeLa cells following treatment with
the TOP1 poison CPT (4 μm) for 45 min or 30 min after IR
(2 Gy). Scale bars, 10 μm. (B) GFP-FUS ﬂuorescence was
detected in HeLa cells treated with DMSO vehicle or with
4 μm of CPT for 1 h. Anti-ﬁbrillarin immunostaining was
used to stain nucleoli. Numbers are the mean
percentage (±SD) of GFP-positive cells with GFP-FUS
nucleolar localization in three independent
experiments (50 cells per experiment). Scale bars,
10 μm. (C, D) Endogenous FUS was detected by indirect
immunoﬂuorescence in A549 cells (C) and primary
human ﬁbroblasts (D) treated with DMSO vehicle or
4 μM CPT for 45 min. Scale bars, 5 μm.
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relative lack of measurable impact of IR on transcription (Fig 7A,
right). To rule out that the increased sensitivity to CPT was due to
differences in genetic background between the unaffected and ALS
ﬁbroblasts, we compared HeLa cells expressing either wild-type
GFP-FUS or the ALS-associated mutant derivatives GFP-FUSR521C
and GFP-FUSP525L (Fig 7B). Similar to ALS patient ﬁbroblasts, HeLa
cells expressing GFP-FUSR521C and GFP-FUSP525L were more sensitive
to CPT than HeLa cells expressing wild-type GFP-FUS, supporting
the notion that FUS mutations associated with ALS confer hyper-
sensitivity to TOP1-induced DNA breakage.
Discussion
FUS is a hnRNP that belongs to the FET/TET family of RNA-binding
proteins comprising FUS/TLS, EWSR1, and TAF15 (15,18). Under
physiological conditions, FUS is localized primarily in the nucleus,
although it can shuttle between the nucleus and cytoplasm (44).
FUS binds a number of nucleic acids and nucleic acid–like struc-
tures including single- and double-stranded DNA, RNA, and poly
(ADP-ribose), but the precise biochemical function of FUS is unclear
(15, 18, 21, 22). Of these activities, RNA binding is most likely critical
because FUS inﬂuences the synthesis and processing of a large
number of pre-mRNAs (45). Consistent with this, FUS interacts with a
variety of transcription factors and with the C-terminal domain of
RNA Pol II, regulating its phosphorylation during transcription (38,
46). Notably, ALS-associated mutations in FUS have been reported
to reduce binding to Pol II (47) and transcriptionally active chro-
matin (48).
Recently, it was suggested that FUS is required for the repair of
DNA DSBs (21, 23). RNAi-mediated depletion of FUS and FUS carrying
familial ALS mutations was reported to reduce the efﬁciency of DSB
Figure 3. FUS relocalises to nucleoli in response to
TOP1-induced DNA breakage in neurons.
(A) Endogenous FUS and B23 (nucleophosmin; nucleolar
marker) were detected by indirect immunoﬂuorescence
in mouse cortical neurons following incubation with
DMSO vehicle or 4 μM CPT for 45 min. Scale bar, 5 μm. (B)
FUS-GFP was detected by direct ﬂuorescence in human
spinal motor neurons after treatment with either DMSO
vehicle or 4 μM CPT for 1 h. Fibrillarin and MAP2 were
detected by indirect immunoﬂuorescence to stain
nucleoli and neurons, respectively. Numbers are the
mean percentage (±SD) of MAP-positive cells with FUS-
GFP nucleolar localization in three independent
experiments (50 cells per experiment). Scale bar, 10 μm.
(C) FUS-GFP was detected by direct ﬂuorescence in
human spinal motor neurons after treatment with
either DMSO vehicle or 4 μM CPT for 1 h. Choline
acetyltransferase (ChAT) was detected by indirect
immunoﬂuorescence to conﬁrm the identity of motor
neurons. Numbers are the percentage of ChAT-positive
cells with FUS-GFP nucleolar localization (n = 100 cells).
Scale bar, 10 μm. Zoomed areas are shown (right).
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repair by both NHEJ and homologous recombination, the two
primary mechanisms by which DSBs are repaired. However, we
failed to observe a defect in our experiments in DSB repair in
ALS ﬁbroblasts harbouring the pathogenic FUS mutation, R521H,
following either IR or following treatment with etoposide or CPT.
A similar lack of defect in repair rate was reported in human
Figure 4. FUS nucleolar relocalisation is not a direct
response to DNA breakage.
(A) GFP-FUS ﬂuorescence and ﬁbrillarin
immunoﬂuorescence (a nucleolar marker) were
detected in HeLa cells preincubated or not with PARP
inhibitor (10 μM KU0058948; PARPi) for 1 h before a 1-h
incubation with 4 μMCPT. The cells were counterstained
with DAPI to detect nuclei. Scale bars, 10 μm. (B) HeLa
cells were preincubated or not with 5 μM ATR kinase
inhibitor (ATRi) for 15 min, 10 μM ATM inhibitor (ATMi,
KU55933) for 30 min, or 5 μM DNA-PK inhibitor (DNA-PKi,
NU7441) for 1 h before a 1-h incubation with 4 μM CPT.
The cells were counterstained with DAPI to detect
nuclei. Scale bars, 10 μm. (C) GFP-FUS ﬂuorescence and
53BP1 immunoﬂuorescence (a DSB marker) were
detected in HeLa cells following treatment with 4 μM of
CPT for 1 h (left) or following IR (2 Gy) (right). Scale bars,
10 μm.
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Figure 5. FUS nucleolar relocalisation is reversible and triggered by transcriptional stress.
(A) Top: representative ScanR images of 5-EU pulse labelling in HeLa cells treated with DMSO vehicle or 4 μM CPT for 1 h (left) or following irradiation (2 Gy) (right). Bottom:
quantiﬁcation of EU signal from >500 cells per sample using Olympus ScanR analysis software. Data are the mean (±SEM) of three independent experiments. Statistically
signiﬁcant differences are indicated (two-tailed t test; **P < 0.01). (B) GFP-FUS, ﬁbrillarin, and EU were detected by direct ﬂuorescence (GFP), immunoﬂuorescence
(ﬁbrillarin), or Click Chemistry (EU) in HeLa cells treated with DMSO vehicle or 4 μM CPT for 1 h (CPT), and in CPT-treated HeLa cells following subsequent incubation in
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patient-derivedmotor neurons (37). Notably, we have also failed to
detect a difference between ALS ﬁbroblasts and unaffected sibling
control in the rate of DNA single-strand break (SSB) repair, fol-
lowing treatment with H2O2 or CPT (unpublished observations).
This contrasts with a recent study in which FUS was reported to
promote SSB repair by facilitating XRCC1 recruitment and ligation
at SSBs (49). These conﬂicting results may reﬂect differences in the
assays or cell lines used in the studies.
Although we did not detect a requirement for FUS for DSB repair,
our current data support the idea that FUS is involved in the re-
sponse to transcriptional stress arising from TOP1-induced DNA
breakage. We discovered that FUS relocates from the nucleoplasm
to the nucleolus in a rapid and dynamicmanner following the TOP1-
induced DNA breakage by CPT. TOP1 creates transient SSBs to re-
lease torsional constraints in DNA during processes such as DNA
replication and transcription (31). Normally, these breaks are
resealed by the topoisomerase at the end of each catalytic cycle,
but on occasion they can become abortive and require cellular SSB
or DSB repair pathways for their removal (reviewed in reference 31).
Topoisomerase “poisons” such as CPT induce this type of DNA
breakage by inhibiting the religation activity of TOP1 (reviewed
in reference 50). The threat posed by topoisomerase-induced
breaks is illustrated by the existence of human hereditary dis-
eases in which the repair of these breaks is attenuated, resulting
in neurodevelopmental pathology and/or progressive neuro-
degeneration (32, 33, 35, 51, 52). Importantly, the relocalisation of
FUS to nucleoli triggered by TOP1-induced breakage raises the
possibility that these lesions may also be an etiological factor in
ALS, a possibility supported by our observations that this response
to CPT was also detected in human iPSC-derived spinal motor
neurons, and by the sensitivity of ALS patient-derived ﬁbroblasts
and HeLa cells expressing ALS-associated FUS mutations to CPT.
Under normal conditions, FUS was primarily detected outside of
nucleoli, but accumulated in the nucleoli and/or at the nucleolar
periphery in a rapid and dynamic manner following TOP1-induced
DNA breakage. The relocalisation of FUS to the nucleolus was not a
result of the DNA breaks per se because it was not induced by IR at
doses that induced similar if not more DNA breaks than CPT. Rather,
the relocalisation of FUS to nucleoli appeared to result from the Pol
II transcriptional stress imposed by TOP1-induced breaks. Con-
sistent with this conclusion, other inhibitors of Pol II such as ac-
tinomycin D and DRB similarly triggered FUS relocalisation to
nucleoli (this work and [53, 54, 55]). Intriguingly, TOP1 is enriched in
nucleoli and is associated with ribosomal genes, possibly to fa-
cilitate rRNA transcription (56,57). Curiously, however, treatment
with DRB or CPT results in the relocalisation of TOP1 out of the
nucleolus, a phenomenon that is opposite to the behaviour of FUS
reported here (56). Whether or not these observations are mech-
anistically related remains to be determined, but it seems likely
that they are part of the same physiological response to tran-
scriptional stress.
We do not yet know what facilitates the movement of FUS to sites
of rRNA synthesis, but unlike FUS recruitment at sites of oxidative
DNA damage (21, 22), it does not appear to be regulated by PARP1 or
by DNA damage response protein kinases and seems not to be
affected by ALS causing FUS mutations. Importantly, the subcellular
relocalisation of FUS to the nucleolus was paralleled at the mo-
lecular level because FUS binding at the rDNA locus increased
following CPT treatment, as measured by chromatin immunopre-
cipitation experiments, and decreased at the transcriptionally
active FOS locus; a gene at which TOP1-induced SSBs are known to
be induced and inhibit Pol II progression (42, 43). Although the FUS
relocalisation to nucleoli observed in our work appeared to be
triggered by Pol II transcriptional stress, it required the rDNA loci at
which FUS was recruited to be transcriptionally active. This was
suggested by the recruitment of FUS speciﬁcally to regions of the
rRNA gene body, but not the promoter, and by the decrease of FUS
relocalisation to rDNA if the initiation of transcription by Pol I was
inhibited by incubation with CX5461. The accumulation of FUS in
nucleoli and/or at the periphery nucleolar may, thus, involve a
direct, or indirect, association with incomplete or partially pro-
cessed rRNA.
What is the purpose of FUS relocalisation to the nucleoli fol-
lowing Pol II inhibition? One possibility is that FUS protein
relocalises to transcriptionally active rDNA loci to protect these
sites from the pathological effects of TOP1-induced SSBs. For
example, the transcriptional blockage induced by TOP1-induced
breaks can promote the formation of potentially pathogenic R
loops, and FUS has been reported to participate in the prevention
and/or repair of R loop–associated DNA damage (24). Alterna-
tively, perhaps FUS regulates the level of pre-rRNA synthesis and/
or processing under conditions of transcriptional stress. Finally,
because FUS is also strongly implicated in pre-mRNA splicing/
processing (reviewed in references 12, 13, 19), perhaps the
relocalisation of FUS to nucleoli helps repress aberrant pre-mRNA
processing following Pol II stalling (24, 38). Although one or more
of the roles played by FUS following relocalisation may be de-
fective in ALS, it should be noted that the relocalisation process
itself is not defective because this phenomenon was similarly
observed by FUS (and TDP-43) proteins that harbour ALS-
associated mutations.
In summary, we show here that FUS (and TDP-43) relocalises
from the nucleoplasm to sites of nucleolar rRNA synthesis in re-
sponse to Pol II transcriptional stress, including that induced by
abortive TOP1 DNA breakage. To our knowledge, these data are the
ﬁrst to demonstrate that FUS is mobilised in response to
topoisomerase-induced DNA breaks. We propose that FUS moves
from sites of stalled Pol II to sites of Pol I activity either to regulate
pre-mRNA synthesis and/or processing during transcriptional
stress, or to modulate some as yet unidentiﬁed aspect of rRNA
biogenesis. Consequently, we suggest that TOP1-induced DNA
breakage is a possible etiological factor in ALS pathology.
CPT-free medium for 10, 30, 60, or 120min. All cells were pulse-labelled with EU for 30min before ﬁxation. Scale bars, 10 μm. (C) GFP-FUS and EU were detected in HeLa cells
treated with either DMSO vehicle, 4 μM CPT for 1 h, actinomycin D (5 nM or 4 μM) for 1 h or 10 μM CX5461 for 3 h. Where indicated, the cells were preincubated with CX5461 for
3 h before a 1-h incubation with 4 μM CPT (CX5461+CPT). Scale bars, 10 μm. (D) GFP-FUS and EU were detected in HeLa cells treated with either DMSO or 100 μM DRB for 30
min. Where indicated, the cells were preincubated with CX5461 for 3 h before a 30-min incubation with 100 μM DRB (CX5461+DRB). Scale bars: (A): 5 μm; (B–D): 10 μm.
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Figure 6. FUS chromatin binding is increased at rDNA following TOP1-induced DNA breakage.
(A) GFP-FUS binding at the indicated regions of FOS was quantiﬁed by chromatin immunoprecipitated/qPCR in HeLa cells stimulated with calcium ionophore (5 μM of
A23187) for 30 min to induce FOS expression, in the presence or absence of 10 μM of CPT. Top: schematic showing the regions of the FOS promoter and exon 4 ampliﬁed by
qPCR. A non-transcribed region of chromosome 5 was also ampliﬁed and quantiﬁed as a control. Data are the mean (±SEM) of four independent experiments. Statistically
nonsigniﬁcant (“ns”) and signiﬁcant (two-tailed t test; *P < 0.05) differences are indicated. (B) Quantiﬁcation of FOS mRNA in serum-starved HeLa cells stimulated with
A23187 to induce FOS for the indicated times in the presence of DMSO vehicle (-CPT) or 10 μMCPT. Top: schematic of the FOS gene showing the region ampliﬁed by qRT-PCR.
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Materials and Methods
Cell culture and drug treatments
The isogenic HeLa stable cell lines expressing inducible GFP-FUS,
GFP-FUS mutants (GFP-FUSR521C and GFP-FUSP525L), GFP-TDP-43,
and GFP-TDP-43 mutants (GFP-TDP-43G298S and GFP-TDP-43M337V)
transgenes were kindly provided by Don Cleveland (University of
California, US) and previously described in references 36, 57. These
cells were grown in DMEM supplemented with 10% FCS, 2 mM
glutamine, and the antibiotics penicillin (100 units/ml) and
streptomycin (100 μg/ml). Transgene expression was induced with
4 μg/ml tetracycline for 48 h. Human A549 cells were grown in DMEM
supplemented with 15% FCS and with penicillin/streptomycin and
glutamine as above. hTERT-immortalised ALS ﬁbroblasts derived
from a 33-yr-old female ALS patient harbouring the heterozygous
mutation R521H and a 44-yr-old clinically unaffected male sibling
were grown in MEM containing 15% FCS, penicillin/streptomycin,
and glutamine. All cells were grown at 37°C and 5% CO2. Where
indicated, the cells were treated with 2 Gy IR or with the following
chemicals: CPT (Sigma-Aldrich) was employed at 4 μM or 10 μM for
the indicated time points, etoposide (VP16; Sigma-Aldrich) was used
at 20 μM for 30 min, PARP inhibitor, KU0058948 hydrochloride
(Axon), at 10 μM for 1 h, ATR inhibitor, ATR kinase inhibitor II
(Calbiochem), at 5 μM for 15 min, ATM inhibitor, KU55933 (Abcam), at
10 μM for 30 min, DNA-PK inhibitor, NU7441 (Tocris), at 5 μM for 1 h,
actinomycin D (Sigma-Aldrich) at 5 nM for 1 h for inhibition of RNA
Pol I, and 4 μM for inhibition of both RNA Pol I and II. The RNA Pol I
inhibitor, CX-5461 (Medchem Express), was used at 10 μM for 3 h.
DRB was used at 100 μM for 30 min. Calcium ionophore for FOS
expression, A23187 (Sigma-Aldrich), was used at 5 μM for the time
indicated in the text.
Mouse cortical neurons
CD1 embryonic mouse brains (18 days post coitum) were removed
from the cranial cavity and placed in HBSS (10594243; Invitrogen)
containing 1% P/S (11528876; Gibco). The meninges were removed,
the hemispheres separated, and coronal slices of each hemisphere
obtained. The coronal sections were placed ﬂat, and an 18-gauge
hypodermic needle was used to separate the cortex from the
remaining brain tissue. The cortical tissue was washed once in HBSS
mRNA levels were quantiﬁed by qRT-PCR and normalized relative to ACTB levels under the same experimental conditions. The normalized value was then expressed
relative to the normalized value from DMSO treated cells. Data are themean (±SEM) of three independent experiments. Statistical signiﬁcance was determined by two-way
ANOVA (*P < 0.05). (C) Quantiﬁcation of FOS pre-mRNA containing (“unspliced”) or lacking (“spliced”) intron 1 in HeLa cells stimulated as above. Top: schematic of the FOS
gene locating the primers used for qRT-PCR and for ampliﬁcation of FOS pre-mRNA in which intron 1 is spliced (E1f and E2r) or unspliced (I1f and E2r). Data are the mean
(±SEM) of three independent experiments. Statistical signiﬁcance was determined by two-way ANOVA (****P < 0.0001). (D) GFP-FUS binding at the indicated regions of the
rDNA loci was quantiﬁed by chromatin immunoprecipitated/qPCR in HeLa cells following incubation with DMSO vehicle or 4 μM CPT for 45 min, with or without co-
incubation with 10 μMCX5461 (Pol I inhibitor) for 3 h. Top: schematic showing the regions of the rDNA repeats ampliﬁed by qPCR are indicated. ACTINwas also ampliﬁed and
quantiﬁed as a control. Data are the mean (±SEM) of four independent experiments. Statistically nonsigniﬁcant (“ns”) and signiﬁcant (two-tailed t test; *P < 0.05, **P < 0.01)
differences are indicated. (E) Anti-RNA:DNA hybrid (S9.6 antibody) ChIP-qPCR at the indicated regions of the rDNA locus in HeLa cells after mock treatment (DMSO) or
treatment with 4 μM CPT for 45 min with or without preincubation with 10 μM CX5461 for 3 h. Data are the mean (±SEM) of six independent experiments.
Figure 7. ALS-associated FUS mutations confer
hypersensitivity to TOP1-induced DNA breakage.
(A) Clonogenic survival of ﬁbroblasts from an ALS
patient expressing FUSR521H and an unaffected sibling
control (Control) in the presence of the indicated
concentrations of CPT (left) or following irradiation at
indicated doses (right). Data are the mean (±SEM) of
three independent experiments. (B) Clonogenic survival
of HeLa cells expressing wild-type GFP-FUS or the ALS-
associated mutants GFP-FUSR521C (GFP-R521C) or GFP-
FUSP525L (GFP-P525L) in the presence of the indicated
concentrations of CPT. Data are the mean (±SEM) of four
independent experiments. Statistically signiﬁcant
differences are indicated (two-factor ANOVA; **P < 0.01,
***P < 0.001).
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before incubation in pre-warmed HBSS containing 0.04% trypsin for
15 min (inverting the tube every 5 min) at 37°C. DNAse (D5025; Sigma-
Aldrich) was added to the solution (0.06 mg/ml) before centrifuging
the cells at 300 g for 10 min. The cell pellet was resuspended in HBSS
containing 1% AlbuMAX (11020-013; Gibco), 0.5 mg/ml of trypsin in-
hibitor (T9003; Sigma-Aldrich), and DNase before dissociating the cells
using a ﬂame polished glass pipette until a single cell suspension was
obtained. Neurons were plated at a density of 50,000 per 13-mm glass
coverslip precoated for 24 h with 0.1 mg/ml of poly-D-lysine (P6407;
Sigma-Aldrich) in Neurobasal media (11570556; Gibco) supplemented
with 1% L-glutamine (11500626; Gibco), 1% P/S, and 1× B27 supple-
ment (17504-044; Thermo Fisher Scientiﬁc).
Differentiation of human neural progenitor cells (NPCs) to spinal
MNs
The generation and culturing of human NPCs has been previ-
ously described (37). NPCs were grown in N2B27 medium (DMEM-
F12/Neurobasal at 50:50 supplemented with 1% penicillin/
streptomycin/glutamine, 1% B27 supplement without vitamin A,
and 0.5% N2 supplement) containing 3 μM CHIR99021 (Cayman),
150 μM L-ascorbic acid (Sigma-Aldrich), and 0.5 μM Smoothened
Agonist (SAG) (Cayman). For differentiation, the medium was
replaced with N2B27 containing 1 ng/ml BDNF (Miltenyi Biotec),
0.2 mM L-ascorbic acid, 1 μM retinoic acid (Sigma-Aldrich), 1 ng/ml
glial cell line-derived neurotrophic factor (GDNF) (Miltenyi Biotec),
and 0.5 μM SAG. On day 8, the medium was changed for inducing
neural maturation to N2B27 containing 5 ng/ml activin A (Miltenyi
Biotec), 0.1 mM dbcAMP (Sigma-Aldrich), 2 ng/ml BDNF, 0.2 mM
L-ascorbic acid, 1 ng/ml TGFβ-3 (Peprotech), and 2 ng/ml GDNF. On
day 10, the cells were seeded on a four-well plate for immuno-
ﬂuorescence and 2.5 μM N-[(3,5-Diﬂuorophenyl)acetyl]-L-alanyl-2-
phenyl]glycine-1,1-dimethylethyl ester (DAPT) (Sigma-Aldrich) and
activin were added to the maturation medium. After 2 d, DAPT and
acitivin were removed and the cells were further grown in the
maturation medium for neural maturation until day 30.
Antibodies
Primary antibodies used were mouse monoclonal anti-phospho-
γH2AX (Ser139) (05-636; 1:1,000 dilution; Merck-Millipore), rabbit
polyclonal anti-53BP1 (A300-272A; 1:400; Bethyl Laboratories), rabbit
polyclonal anti-CENPF (ab5; 1:500 dilution; Abcam), rabbit polyclonal
anti-FUS (NB100-565; 1:400 dilution; Novus), mouse monoclonal anti-
FUS (sc-47711; 1:400; Santa Cruz), mouse monoclonal anti-ﬁbrillarin
(ab4566; 1:500; Abcam), rabbit polyclonal anti-ﬁbrillarin (ab5821; 1:
500; Abcam), and mouse monoclonal anti-nucleophosmin (B23, FC-
61991; 1:500; Thermo Fisher Scientiﬁc). For chromatin immunopre-
cipitation experiments, chromatin immunoprecipitation (ChIP)-grade
anti-GFP (ab290; 5 μg/IP; Abcam) and mouse monoclonal anti RNA:
DNA hybrids (S9.6, ENH001; 5 μg/IP; Kerafast) were used. As neural
markers, mouse monoclonal anti-MAP2 (MAB3418; 1:1,000; Millipore)
and rabbit polyclonal anti-ChAT (AB143; 1:400; Merck) were used.
EU pulse labelling, immunoﬂuorescence, and microscopy
Cells were grown on coverslips, treated with IR/chemicals or not as
indicated above and in the text, and ﬁxed for 10 min in 4%
paraformaldehyde in PBS, or for detection of endogenous FUS in 1%
paraformaldehyde in PBS. After ﬁxation, the cells were washed twice in
PBS, permeabilized for 2 min in 0.2% Triton X-100 in PBS, blocked for 1 h
in 5%BSA in PBS, and incubatedwith the indicated primary antibody for
2 h in 1% BSA in PBS. The cells were then washed (3 × 10 min) in 0.1%
Tween-20 in PBS and incubated for 1 h with the appropriate Alexa
Fluor–conjugated secondary antibody (1:1,000 dilution in 1% BSA in
PBS). The cells were counterstained with DAPI (49,6-diamidino-2-
phenylindole; Sigma-Aldrich) and mounted in Vectashield (Vector
Labs). For γH2AX immunostaining, cells on coverslips were arrested by
serumstarvation by growth inMEMcontaining 0.1% FCS for 4 d and then
treated or not with CPT/Etoposide/IR as described above and in the
text. γH2AX immunofoci were counted (double-blind) in 40 G1-phase
cells from each experimental sample, deﬁned by CENPF immuno-
staining as CENPF-negative. For pulse labelling with 5-EU, the cells were
incubated with 1 mM EU (Invitrogen) for 30 min, ﬁxed, and subjected to
Click Chemistry using a Click-iT Plus Alexa Fluor 647 Picolyl Azide im-
aging kit (Thermo Fisher Scientiﬁc) according to the manufacturer’s
speciﬁcations. Mean ﬂuorescence was quantiﬁed by Olympus ScanR
analysis software from >500 cells for each experiment. High-resolution
microscopy of ﬁxed samples was carried out using either (for HeLa cell
and motor neurons) a Zeiss Apotome AxioObserver Z1 epiﬂuorescence
microscopy system with 40×/1.3 oil Plan-Apochromat objective,
HamamatsuORCA-Flash4.0 LT camera and ZEN 2 core imaging software,
or (for A549 cells and ﬁbroblasts) a Zeiss Axioplan 2 with Plan-
Apochromat 100×/1.4 oil DIC lenses, MicroManager software for ac-
quisition and ImageJ for image processing, or (for mouse cortical
neurons) a Leica TSC SP8 confocal microscope with a 63× objective.
Automated wide-ﬁeld microscopy was performed on an Olympus
ScanR system (motorized IX83 microscope) with ScanR Image Acqui-
sition and Analysis Software, 40×/0.6 (LUCPLFLN 40× PH) dry objectives
and Hamamatsu ORCA-R2 digital CCD camera C10600.
FOS gene expression and splicing
The cells were serum-starved for 3 h and transcription induced by
addition of A23187 for the time points detailed in the text. After 20
min, CPT was either added or not added. RNA was extracted from
pelleted cells using the RNeasy kit (QIAGEN)with an additional DNase
step. Total RNA (1 μg) and oligo (dT) (0.16 μg; Ambion) were heated at
70°C for 5 min, chilled on ice, and reverse transcribed for 2 h at 42°C.
The cDNA was treated with RNase at 37°C for 30 min and puriﬁed
using a PCR puriﬁcation kit (QIAGEN). Aliquots of 2.5 μl were used in
qRT-PCR (25-μl total volume). The cDNA was analyzed by quantitative
PCR (qPCR) by primers in exon 4. The expression data were ﬁrst
normalized to the data for ACTB in the same experimental condition
and then to DMSO-uninduced control. For studying splicing of intron
1, a primer located in FOS intron 2 was used for reverse transcription.
The ratio spliced/unspliced was analyzed by qPCR with primers
spanning exon 1–exon 2 (spliced intron 1), and intron 1–exon 2
(unspliced intron 1). Primer sets are detailed in Table S1.
Chromatin immunoprecipitation
The cells were cross-linked with 1% formaldehyde at room tem-
perature for 10 min, followed by the addition of glycine to 125 mM
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for 5 min at room temperature to terminate cross-linking. Cells
pellets were recovered by scraping, centrifugation, and resus-
pended in 0.3 ml lysis buffer (0.5% SDS, 5 mM EDTA, 50 mM Tris–HCl,
pH 8, 1 mM DTT, 50 μg/ml PMSF, and 1× protease inhibitor cocktail
[P8340; Sigma-Aldrich]). The cells were then sonicated in a Bio-
ruptor at maximum intensity for either 10 min in 20 cycles (30 s off,
30 s on) for GFP ChIP or for 15 min in 30 cycles (30 s off, 30 s on) for
S9.6 ChIP followed by clariﬁcation by centrifugation. Supernatants
were collected, 1/30 volume reserved as whole-cell extract, and the
remainder diluted in 1% Triton X-100, 200 mM NaCl, 10 mM Tris–HCl,
pH 8, 2 mM EDTA, 50 μg/ml PMSF, and 1× protease inhibitor cocktail.
Diluted extract was precleared with magnetic beads (Dynabeads;
Invitrogen) that were blocked with sheared salmon sperm DNA for
1 h at 4°C. Blocked beads were incubated with 5 μg per sample of
anti-GFP antibody (ChIP-grade; Abcam) or anti-RNA:DNA hybrid
antibody (S9.6; Kerafast) for 1 h at room temperature. The pre-
cleared extract was then added, and immunoprecipitation was
performed for 4 h at 4°C. The beads were washed in NaCl buffer
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris–HCl, pH 8, and
500 mM NaCl) followed by LiCl buffer (1% deoxycholate, 1% NP-40,
1 mM EDTA, 10 mM Tris–HCl, pH 8, and 250 mM LiCl). The beads were
then washed two times with TE buffer, and bound material was
eluted with 2% SDS in 1× TE at 65°C for 20 min. Eluates were heated
at 65°C for >6 h to reverse cross-links and treated with 100 μg of
proteinase K at 50°C for 1 h. DNA fragments were puriﬁed (QIAquick
PCR puriﬁcation kit; QIAGEN) and eluted in 100 μl of milliQ water. 3 μl
of the immunoprecipitated material or whole-cell extract (1:100
dilution) was used per 12-μl reaction of a SYBR Green–based
quantitative real-time PCR using a Stratagene MX3005P system. The
set of primers is detailed in Table S1.
Clonogenic survival assays
Control and patient ﬁbroblasts were plated in 10-cm dishes and
were allowed to settle for 24 h before being either treated with
indicated concentrations of CPT (nM) or irradiated with indicated
doses (Gy). The cells were allowed to grow for 19 d in the presence of
CPT or after irradiation. The colonies were rinsed in PBS and ﬁxed/
stained in 70% ethanol/1% methylene blue. HeLa cells were plated
4 h before treatment with the indicated concentrations of CPT (nM),
allowed to grow for 12 d, and stained as described earlier. The
surviving fraction at each dose was calculated by dividing the
average number of colonies in treated dishes by the average
number in untreated dishes.
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